PE20180606A1 - Concentrado que contiene alprostadil - Google Patents
Concentrado que contiene alprostadilInfo
- Publication number
- PE20180606A1 PE20180606A1 PE2018000130A PE2018000130A PE20180606A1 PE 20180606 A1 PE20180606 A1 PE 20180606A1 PE 2018000130 A PE2018000130 A PE 2018000130A PE 2018000130 A PE2018000130 A PE 2018000130A PE 20180606 A1 PE20180606 A1 PE 20180606A1
- Authority
- PE
- Peru
- Prior art keywords
- concentrate containing
- alprostadil
- pharmaceutically acceptable
- organic solvent
- infusion
- Prior art date
Links
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000711 alprostadil Drugs 0.000 title abstract 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title abstract 3
- 239000012141 concentrate Substances 0.000 title abstract 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 238000001361 intraarterial administration Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composicion farmaceutica liquida en forma de un concentrado para la preparacion de una solucion para infusion, que contiene, especialmente que esta constituida por, alprostadil (prostaglandina E1) como principio activo, disuelto en un disolvente organico farmaceuticamente aceptable o en una mezcla de disolventes de al menos un disolvente organico farmaceuticamente aceptable y agua, para uso en el tratamiento de enfermedad arterial oclusiva periferica (EAOP) mediante infusion intrarterial (i.a.).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ATA50664/2015A AT517555A1 (de) | 2015-07-27 | 2015-07-27 | Konzentrat enthaltend Alprostadil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180606A1 true PE20180606A1 (es) | 2018-04-09 |
Family
ID=56852016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000130A PE20180606A1 (es) | 2015-07-27 | 2016-07-25 | Concentrado que contiene alprostadil |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3328357B1 (es) |
| AR (1) | AR105503A1 (es) |
| AT (1) | AT517555A1 (es) |
| BR (1) | BR112018000525A2 (es) |
| CO (1) | CO2018000526A2 (es) |
| MX (1) | MX2018001041A (es) |
| PE (1) | PE20180606A1 (es) |
| WO (1) | WO2017015691A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05864B1 (et) * | 2021-12-22 | 2024-02-15 | Aktsiaselts Kevelt | 3-hüdroksütsüklopentoonitsüklit sisaldava ühendi kompositsioon ja meetod selle stabiliseerimiseks |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4309579C3 (de) * | 1993-03-24 | 2000-01-27 | Sanol Arznei Schwarz Gmbh | Pharmazeutische Zusammensetzung in Form einer Packung |
-
2015
- 2015-07-27 AT ATA50664/2015A patent/AT517555A1/de not_active Application Discontinuation
-
2016
- 2016-07-25 PE PE2018000130A patent/PE20180606A1/es unknown
- 2016-07-25 BR BR112018000525-8A patent/BR112018000525A2/pt not_active IP Right Cessation
- 2016-07-25 EP EP16759665.9A patent/EP3328357B1/de active Active
- 2016-07-25 MX MX2018001041A patent/MX2018001041A/es unknown
- 2016-07-25 WO PCT/AT2016/060019 patent/WO2017015691A1/de not_active Ceased
- 2016-07-27 AR ARP160102284A patent/AR105503A1/es unknown
-
2018
- 2018-01-19 CO CONC2018/0000526A patent/CO2018000526A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018000525A2 (pt) | 2018-09-18 |
| AT517555A1 (de) | 2017-02-15 |
| WO2017015691A1 (de) | 2017-02-02 |
| MX2018001041A (es) | 2018-06-07 |
| EP3328357A1 (de) | 2018-06-06 |
| AR105503A1 (es) | 2017-10-11 |
| EP3328357B1 (de) | 2020-12-09 |
| CO2018000526A2 (es) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003091A1 (es) | Terapia de combinación. | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| MX2015000990A (es) | Analogos del glucagon. | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| CL2015001652A1 (es) | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| CL2014003012A1 (es) | Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| CL2015001943A1 (es) | Derivados de bencilamina | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
| PE20180606A1 (es) | Concentrado que contiene alprostadil | |
| MX2016008729A (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. | |
| CO2018006865A2 (es) | Métodos y composiciones para tratar una corriente que comprende petróleo crudo y agua | |
| GT201600190A (es) | Compuestos químicos | |
| PE20170934A1 (es) | Acido palmitoleico para uso en la inhibicion de la fijacion de piojos de mar a los peces | |
| CL2018003269A1 (es) | Ácidos carboxílicos para aplicación en la primera infancia. | |
| PE20180466A1 (es) | Concentrado que contiene alprostadil |